NONOF Quote, Financials, Valuation and Earnings

Genmab A/S has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 39.24%. Novo Nordisk A/S's return on equity of 68.76% beat Genmab A/S's return on equity of 28.3%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling downside risk potential of -13.64%. On the other hand Genmab A/S has an analysts' consensus of $37.81 which suggests that it could grow by 17.25%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 34.99% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.066%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 2.77%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Genmab A/S quarterly revenues of $1B. Novo Nordisk A/S's net income of $3.1B is higher than Genmab A/S's net income of $399.2M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 18.21x while Genmab A/S's PE ratio is 13.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.96x versus 5.65x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 31.72%. Novo Nordisk A/S's return on equity of 68.76% beat Eli Lilly & Co.'s return on equity of 106.26%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling downside risk potential of -13.64%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.79 which suggests that it could grow by 6.97%. Given that Eli Lilly & Co. has higher upside potential than Novo Nordisk A/S, analysts believe Eli Lilly & Co. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 34.99% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 2.77%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Novo Nordisk A/S's net income of $3.1B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 18.21x while Eli Lilly & Co.'s PE ratio is 51.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.96x versus 15.93x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 21.32%. Novo Nordisk A/S's return on equity of 68.76% beat Pfizer Inc.'s return on equity of 10.84%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling downside risk potential of -13.64%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Pfizer Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Pfizer Inc. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 34.99% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 2.77%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Novo Nordisk A/S quarterly revenues are $11.7B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Novo Nordisk A/S's net income of $3.1B is lower than Pfizer Inc.'s net income of $3.6B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 18.21x while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.96x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.